Search results for "Criteria"

showing 10 items of 582 documents

Effect of a Passive Tuned Mass Damper on Offshore Installation of a Wind Turbine Nacelle

2021

Abstract Although the installation of offshore wind turbines takes place in calm seas, successful mating of wind turbine components can be challenging due to the relative motions between the two mating parts. This work investigates the effect of a passive tuned mass damper on the mating processes of a nacelle for a 10-megawatt (MW) offshore wind turbine. A nacelle with lifting wires and a monopile with a mass damper are respectively modelled using the multibody formulation in the HAWC2 program. A single mass damper is tuned to target at the first natural period of the monopile and is coupled to the main program using a dynamic link library. Afterwards, numerical simulations were carried out…

Offshore wind turbinesWind powerTurbulenceNacellebusiness.industryTurbineCivil EngineeringVDP::Teknologi: 500::Elektrotekniske fag: 540DamperInstallation methodJack-up vesselOffshore wind powerTuned mass damperContact/impact analysisEnvironmental scienceResponse-based criteriaEngineering and TechnologySubmarine pipelineCrane operationbusinessMarine engineering
researchProduct

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

2018

Background: The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations. Methods: Clinical data and KRAS mutational status were analysed in patients treated with nivolumab within the Italian Expanded Access Program. Objective response rate, progression-free survival and overall survival were evaluated. Patients were monitored for adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events. Results: Among 530 patients evaluated for KRAS mutations, 206 (39%) were positive while 324 (61%) were KRAS wild-type mutations. KRAS status did not influence nivolumab efficacy in terms of …

OncologyAdultMalemedicine.medical_specialtyCancer Researchmedicine.disease_causePredictive markersArticleProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineCarcinoma80 and overHumansProgression-free survivalLung cancerNon-Small-Cell LungneoplasmsAgedAged 80 and overbusiness.industryCarcinomaCancerCommon Terminology Criteria for Adverse EventsMiddle Agedmedicine.diseasedigestive system diseasesProgression-Free Survivalrespiratory tract diseasesNivolumabOncologyAdult; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Female; Humans; Male; Middle Aged; Mutation; Nivolumab; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); ImmunotherapyOncology; Cancer Research030220 oncology & carcinogenesisExpanded accessMutationFemaleKRASImmunotherapyNivolumabbusinessNon-small-cell lung cancer
researchProduct

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast…

2012

Background: Targeted therapy options in HER2-negative breast cancer are limited. This open-label, multicenter phase IB dose-escalation trial was conducted to determine safety, tolerability, and antitumor activity of a combination of docetaxel (Taxotere) and increasing doses of adecatumumab, a human IgG1 antibody targeting epithelial cell adhesion molecule (EpCAM), in EpCAM-positive relapsed or primary refractory advanced-stage breast cancer. Patients and methods: Patients pretreated with up to four prior chemotherapy regimens received increasing adecatumumab doses either every 3 weeks (q3w) or weekly (qw) combined with docetaxel (100 mg/m 2 q3w). Primary end points were safety and tolerabil…

OncologyAdultmedicine.medical_specialtyMedizinBreast NeoplasmsDocetaxelAntibodies Monoclonal HumanizedDrug Administration ScheduleBreast cancerAdecatumumabLeukocytopeniaAntigens NeoplasmInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedbusiness.industryLiver NeoplasmsAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseEpithelial Cell Adhesion MoleculeMetastatic breast cancerSurgeryTreatment OutcomeOncologyDocetaxelTolerabilityResponse Evaluation Criteria in Solid TumorsDrug Resistance NeoplasmFemaleTaxoidsBreast diseaseNeoplasm Recurrence LocalbusinessCell Adhesion MoleculesLeukocyte Disordersmedicine.drug
researchProduct

Is APOE ε4 associated with cognitive performance in early MS?

2020

ObjectiveTo assess the impact of APOE polymorphisms on cognitive performance in patients newly diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS).MethodsThis multicenter cohort study included 552 untreated patients recently diagnosed with CIS or RRMS according to the 2005 revised McDonald criteria. The single nucleotide polymorphisms rs429358 (ε4) and rs7412 (ε2) of the APOE haplotype were assessed by allelic discrimination assays. Cognitive performance was evaluated using the 3-second paced auditory serial addition test and the Multiple Sclerosis Inventory Cognition (MUSIC). Sum scores were calculated to approximate the overall cognitive performance and memo…

OncologyApolipoprotein Emedicine.medical_specialtyClinically isolated syndromemedicine.diagnostic_testPaced Auditory Serial Addition Testbusiness.industryMultiple sclerosisCognitionMcDonald criteria610 Medicine & healthmedicine.diseaseNeurologyInternal medicinemedicineddc:610Neurology (clinical)Effects of sleep deprivation on cognitive performance610 Medicine & healthFunction and Dysfunction of the Nervous SystembusinessCohort study
researchProduct

Assessment of treatment response in hepatocellular carcinoma: a review of the literature

2013

Hepatocellular carcinoma (HCC) has a high incidence all over the world. Even if the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and could have a key role in clinical management. Since 1950 several radiological response criteria have been applied; however, it was not until 2000 that specific criteria for HCC were introduced by the European Association for the Study of the Liver (EASL), and these were then standardized in 2010 with the development of the modified Response Evaluation Criteria for Solid Tumors (mRECIST) for HCC. The purpose of this brief review is to compare data in literature regarding the application an…

OncologyCancer ResearchTreatment responsemedicine.medical_specialtyCarcinoma HepatocellularLiver Function TestsInternal medicineClinical endpointHumansMedicineResponse criteriaNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industrySurrogate endpointIncidence (epidemiology)Liver NeoplasmsGeneral MedicinePrognosismedicine.diseaseSurvival Analysisdigestive system diseasesRadiographyClinical PracticeTreatment OutcomeOncologyRadiological weaponHepatocellular carcinomabusinessFuture Oncology
researchProduct

70 Patient reported outcome in platinum-resistant recurrent ovarian cancer and metastatic breast cancer treated with metronomic chemotherapy

2021

Introduction/Background* In the treatment of both platinum-resistant recurrent ovarian cancer (ROC) and metastatic breast cancer (MBC), symptom control and maintenance of quality of life (QoL) play a crucial role. In the advanced stage of disease, metronomic chemotherapy (MCT) may be a favourable treatment option. The aim of this study is to assess the QoL of heavily pretreated patients with ROC and MBC treated with MCT. Methodology PROmetronomic, FoR.UM 19-02193, is a monocentric, open-label, single-arm observational study to assess health-related patient-reported outcome data in ROC and MBC patients treated with MCT (cyclophosphamide 50 mg p.o. daily ± methotrexate 2.5 mg p.o. every other…

OncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancerCommon Terminology Criteria for Adverse Eventsmedicine.diseaseMetronomic ChemotherapyMetastatic breast cancerTolerabilityQuality of lifeInternal medicinemedicinePatient-reported outcomebusinessOvarian cancer
researchProduct

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Reg…

2015

Background The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking. Aim To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival. Methods A comprehensive search of the literature was performed in electronic database…

OncologyGenetics and Molecular Biology (all)medicine.medical_specialtyCarcinoma HepatocellularPrognosiConcordancePopulationMEDLINElcsh:MedicineCarcinoma Hepatocellular; Humans; Liver Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Cochrane LibraryBiochemistryInternal medicinemedicineHumanseducationlcsh:ScienceSurvival analysiseducation.field_of_studyMultidisciplinaryBiochemistry Genetics and Molecular Biology (all)Carcinoma Hepatocellular; Humans; Liver Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)business.industryMedicine (all)CarcinomaLiver Neoplasmslcsh:RHepatocellularPrognosisSurvival AnalysisConfidence intervalSurgeryTreatment OutcomeAgricultural and Biological Sciences (all)Response Evaluation Criteria in Solid TumorsLiver NeoplasmMeta-analysislcsh:QSurvival AnalysibusinessHumanResearch ArticlePLoS ONE
researchProduct

Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experi…

2017

Background/Aim: To evaluate the role of densitometric criterion using the Choi Criteria in the assessment of the response to antiangiogenic treatments of metastatic colorectal cancer (mCRC) compared to the RECIST criteria. Patients and Methods: Fifty-four patients (mean age=50.6 years ) affected by advanced colorectal cancer and with hepatic and possibly peritoneal and pulmonary metastases, that can be treated with bevacizumab, were prospectively evaluated by computerized tomography (CT) scan. Metastases were also evaluated by CT in onedimensional form according to RECIST. Results: Results show that in 58% of analyzed cases, stable disease according to RECIST coincided with stable disease a…

OncologyMalemedicine.medical_specialtyCancer ResearchBevacizumabDensitometric criteriaColorectal cancerAntiangiogenic therapyAngiogenesis InhibitorsColorectal NeoplasmAdvanced colorectal cancerStable DiseaseChoi CriteriaInternal medicinePartial responseMultidetector Computed TomographymedicineHumansDemographybusiness.industryDisease progressionLiver NeoplasmsMean ageGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeRECISTOncologyItalyLiver NeoplasmCHOIFemaleMetastatic colorectal cancer (mCRC)businessColorectal Neoplasmsmedicine.drugAngiogenesis InhibitorHumanDensitometryAnticancer research
researchProduct

Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patie…

2020

Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Although Milan Criteria (MC) generalized the practice of LT for HCC and improved outcomes, its predictive character has degraded with increasing candidate and oncological heterogeneity. We sought to validate and recalibrate a previously developed, preoperatively calculated, continuous risk score, the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC), in an international cohort. From 2002 to 2014, 4,089 patients (both MC in and out [25.2%]) across 16 centers in North America, Europe, and Asia were included. A continuous risk score using pre-…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentInternational CooperationPROGNOSTIC SCORETumor burdengastroenterologyLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCORELiver transplantationMilan criteriaRisk AssessmentLiver diseaseInternal medicinemedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapiesHEPATOCELLULAR CARCINOMARetrospective StudiesOUTCOMEFramingham Risk ScoreHepatologybusiness.industryPoorly differentiatedLiver Neoplasmshepatocelluar cancerMiddle Agedmedicine.diseasePrognosisSettore MED/18Liver TransplantationRISK FACTORSHepatocellular carcinomaCohortlocoregional therapiesFemalebusinessHepatology (Baltimore, Md.)References
researchProduct

Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodie…

2021

Background: Metastatic colorectal cancer (mCRC) with wild type expression of RAS and RAF genes can be treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, such as cetuximab, in combination with chemotherapy. Skin toxicity represents the most serious and frequent side effect in these patients. Skin manifestations occur in approximately 80% of patients. In this study, we investigated the consequences on body image and quality of life (QoL) of patients with severe skin toxicity. Methods: One hundred patients were enrolled with mCRC. All patients signed informed consent and completed questionnaires to assess QoL and body discomfort. Toxicity was assessed on Common Te…

OncologyQuality of lifeCancer Researchmedicine.medical_specialtySide effectColorectal cancermedicine.medical_treatmentPsychological reactionsCetuximabMetastasesQuality of lifeInternal medicinemedicineChemotherapyChemotherapySkin rashCetuximabintegumentary systembusiness.industryMetastatic colorectal carcinomaCommon Terminology Criteria for Adverse Eventsmedicine.diseaseRashhumanitiesOncologyToxicityOriginal Articlemedicine.symptombusinessmedicine.drugWorld journal of oncology
researchProduct